198P Adebrelimab with concurrent chemoradiation (cCRT) for limited-stage small cell lung cancer (LS-SCLC): Safety run-in results of a phase III trial

肿瘤科 医学 肺癌 阶段(地层学) 内科学 生物 古生物学
作者
Ying Cheng,Hui Wang,X. Min,Dong Hu,Q-M. Wang,B. Li,Aimin Liu,Chunyu Liu,Lingdi Zhao,Ying Liu,Chun‐Ming Wu,Xin Yan,X.-C. Zhang,Huijuan Cui,Jian Zhang,Kang Ma,Ling Yang
出处
期刊:ESMO open [Elsevier BV]
卷期号:9: 102771-102771 被引量:2
标识
DOI:10.1016/j.esmoop.2024.102771
摘要

cCRT is the standard of care in LS-SCLC, but LS-SCLC still represents a significant unmet medical need with a median survival of 25 to 30 mo. Addition of the anti-PD-L1 antibody adebrelimab to carboplatin and etoposide has demonstrated survival benefits in extensive-stage SCLC in the phase 3 CAPSTONE-1 trial. This ongoing, 2-stage, phase 3 study aims to evaluate cCRT with adebrelimab in LS-SCLC. In the safety run-in stage, patients with pathologically confirmed, unresectable LS-SCLC were enrolled. Treatment consisted of four 3-week cycles of adebrelimab (20 mg/kg, iv, d1, Q3W) plus carboplatin (AUC 5, iv, d1, Q3W) and etoposide (100 mg/m2, iv, d1, 2, 3, Q3W), with thoracic radiotherapy started on cycle 3 (60 Gy/2 Gy, QD, 6 weeks). Following cCRT, patients received maintenance adebrelimab (20 mg/kg, iv, Q3W) until disease progression or unacceptable toxicities. The primary endpoint was safety. In the safety run-in stage, 28 patients were enrolled and all received adebrelimab with cCRT. As of Oct. 31, 2023, median follow-up was 29.4 mo (range 6.5-33.3). Grade ≥3 TRAEs occurred in 27 (96.4%) patients; all events with an incidence of ≥10% were hematological toxicities. Four (14.3%) patients had treatment-related pneumonitis and one (3.6%) had treatment-related immune-mediated lung disease (all grade 2). TRAEs led to treatment discontinuation in one (3.6%; infusion-related reactions) patient. There were no deaths due to TRAEs. Confirmed ORR was 92.9% (26/28; 95% CI 76.5-99.1) and DCR was 100% (28/28; 95% CI 87.7-100). Among responders, median DoR was 20.1 mo (95% CI 7.7-not reached [NR]; 11/26 responses ongoing). Median PFS was 17.9 mo (95% CI 8.8-NR). Median OS was NR and the OS rate at 2 years was 64.3% (95% CI 43.8-78.9). In the safety run-in stage, adebrelimab with cCRT showed acceptable tolerability and favorable efficacy outcomes in LS-SCLC. The randomized, double-blind, placebo-controlled stage of the trial is ongoing to further assess the regimen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脑洞疼应助jbhb采纳,获得10
2秒前
2秒前
gs19960828完成签到,获得积分10
3秒前
Younglee完成签到,获得积分10
7秒前
7秒前
xiaoxuan完成签到,获得积分10
8秒前
9秒前
Garnieta完成签到,获得积分10
10秒前
彤光赫显发布了新的文献求助10
11秒前
11秒前
浔城游侠完成签到,获得积分10
12秒前
12秒前
失眠的板栗完成签到,获得积分10
13秒前
蝶步韶华发布了新的文献求助10
15秒前
Jay发布了新的文献求助10
15秒前
jbhb发布了新的文献求助10
17秒前
幸运星发布了新的文献求助10
20秒前
20秒前
20秒前
21秒前
23秒前
小王完成签到 ,获得积分10
26秒前
liuyunhao7207发布了新的文献求助10
26秒前
Nugget发布了新的文献求助10
26秒前
量子星尘发布了新的文献求助10
29秒前
蝶步韶华完成签到,获得积分10
29秒前
SciGPT应助wade采纳,获得10
31秒前
稳重水卉完成签到,获得积分10
34秒前
我是老大应助111采纳,获得10
35秒前
37秒前
情怀应助天真的高山采纳,获得10
38秒前
万能图书馆应助高木采纳,获得10
39秒前
积极以云完成签到,获得积分10
40秒前
40秒前
42秒前
CyrusSo524应助zzz采纳,获得10
43秒前
123完成签到,获得积分10
44秒前
兔子先生完成签到 ,获得积分10
45秒前
向日葵完成签到,获得积分10
47秒前
科研通AI5应助天天采纳,获得10
47秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174